New Jersey-based drugmaker Celgene and certain former executives were hit with a securities lawsuit Tuesday in New Jersey District Court. The 144-page complaint contends that the defendants misled investors about multiple problems with sales of the psoriasis drug Otezla, as well as the viability of the multiple sclerosis drug Ozanimod. The case was brought by Rolnick Kramer Sadighi on behalf of Blackstone Alternative Investment Fund and other plaintiffs, Counsel have not yet appeared for the defendants. The case is 2:22-cv-02404, Healthcor Offshore Master Fund, L.P. et al v. Celgene Corporation et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector. 

Read the document here: